RxDoctor Payments Data

Salvatore Desimone, DO

Ophthalmology · Philadelphia, PANPI 1083618029

Payments from drug & device makers

$382in general payments, 2019–2025

Across 16 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$124
  • AbbVie$64
  • Tarsus Pharmaceuticals, Inc.$50
  • Amgen$30
  • Astellas Pharma US Inc$23
  • Alcon$22
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$36595%
  • Gifts$175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$382 in reported general payments places this provider in the 30th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$107,793
Medicare patients
498
Services billed
1,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost124$56,637
Travoprost29$4,882
Latanoprost671$4,365
SimbrinzaBrinzolamide/Brimonidine Tart19$3,776
Prednisolone Acetate65$2,258
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat119$1,950
Brimonidine Tartrate171$1,787
ErythromycinErythromycin Base127$1,324
Timolol Maleate190$1,142
Dorzolamide Hcl47$770
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha78$699
Ketorolac Tromethamine19$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$64$56,637124 claims
AlconSimbrinza$22$3,77619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →